CD274 and neoplasm: The chimeric conjugates demonstrated consistent therapeutic potential across experimental models: it first effectively reduced PD-L1 levels in tumour cell lines, including those with high baseline PD-L1 expression and others resistant to immune checkpoint inhibitors.